Regeneron Pharmaceuticals
REGN
605 hedge funds and large institutions have $32.3B invested in Regeneron Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 72 funds opening new positions, 226 increasing their positions, 211 reducing their positions, and 64 closing their positions.
13% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 64
7% more repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 211
0% more funds holding
Funds holding: 603 → 605 (+2)
0.65% less ownership
Funds ownership: 70% → 69.35% (-0.65%)
10% less capital invested
Capital invested by funds: $35.9B → $32.3B (-$3.51B)
22% less call options, than puts
Call options by funds: $973M | Put options by funds: $1.24B
27% less funds holding in top 10
Funds holding in top 10: 22 → 16 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$232M |
| 2 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$155M |
| 3 |
Millennium Management
New York
|
+$90.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$329M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$228M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$176M |
| 4 |
Polen Capital Management
Boca Raton,
Florida
|
-$101M |
| 5 |
PC
PointState Capital
New York
|
-$78.2M |
REGN Hedge Fund Activity: Q3 2017 in Review
605 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2017, worth a combined $32.3B — down 9.8% from $35.9B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new REGN positions and 64 closed out — a net gain of 8 holders — while 226 added to existing stakes and 211 trimmed.
The largest buyer was Bank of America, adding an estimated $232M. The largest seller was Wellington Management Group, cutting an estimated $329M.
- 605 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2017, up from 603 in Q2 2017.
- Funds reported $32.3B of Regeneron Pharmaceuticals stock for Q3 2017, down 9.8% quarter-over-quarter.
- 72 funds opened new Regeneron Pharmaceuticals positions in Q3 2017 and 64 closed out, a net change of +8 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2017 was Bank of America, an estimated $232M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2017 was Wellington Management Group, an estimated $329M sold.
Based on aggregated 13F filings for Q3 2017.